Synthesis and Assessment of 99mTc Chelate-Conjugated Alendronate for Development of Specific Radiopharmaceuticals

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Cancer Biotherapy and Radiopharmaceuticals

• Publication date

  2009-04-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1089/cbr.2008.0551PMID 19409043
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Synthesis, characterization and biological activity of Schiff base analogues of indole-3-carboxaldehyde.

  2008cited by this paper
• Synthesis and biological properties of 4-(3H)-quinazolone derivatives.

  2007cited by this paper
• A clinical comparison of 99mTc-DPD and two 99mTc-MDP agents

  2004cited by this paper
• A comparison between the diagnostic efficacy of 99mTc-MDP, 99mTc-DPD and 99mTc-HDP for the detection of bone metastases

  2004cited by this paper
• Complexes of divalent transition metal ions with bis(aminomethyl)phosphinic acid in aqueous solution and in the solid state

  2003cited by this paper
• Chapter 1 – Structure and Development of the Skeleton

  2002cited by this paper
• The palliative management of skeletal metastases in prostate cancer: use of bone-seeking radionuclides and bisphosphonates.

  2001cited by this paper
• Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase.

  2000cited by this paper
• Therapeutic approaches to bone diseases.

  2000cited by this paper
• Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial.

  1998cited by this paper
• Alendronate Prevents Postmenopausal Bone Loss in Women without Osteoporosis: A Double-Blind, Randomized, Controlled Trial

  1998cited by this paper
• Bisphosphonates: mechanisms of action

  1998cited by this paper
• Prevention of bone loss with alendronate in postmenopausal women under 60 years of age.

  1998cited by this paper
• Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group.

  1998cited by this paper
• Radiopharmacokinetic data for 99mTc-ABP--a new radiopharmaceutical for bone scanning: comparison with 99mTc-MDP.

  1997cited by this paper
• Rhenium-188 hydroxyethylidene diphosphonate: a new generator-produced radiotherapeutic drug of potential value for the treatment of bone metastases

  1997cited by this paper
• Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation.

  1997cited by this paper
• Prevention of nonvertebral fractures by alendronate. A meta-analysis. Alendronate Osteoporosis Treatment Study Groups.

  1997cited by this paper
• Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.

  1996cited by this paper
• Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis.

  1996cited by this paper
• Bisphosphonates: mechanisms of action.

  1996cited by this paper
• Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis.

  1996cited by this paper
• Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

  1995cited by this paper
• Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis.

  1995cited by this paper
• Alendronate treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling.

  1995cited by this paper
• ÉTUDE DE LA COMPLEXATION DU CADMIUM ET DU ZINC AVEC L'ALENDRONATE (ACIDE 4-AMINO-1-HYDROXYBUTYLIDÈNE-1′1-BISPHOSPHONIQUE)

  1995cited by this paper
• Re-186(Sn) HEDP for treatment of multiple metastatic foci in bone: human biodistribution and dosimetric studies.

  1988cited by this paper
• Skeletal localization of samarium-153 chelates: potential therapeutic bone agents.

  1987cited by this paper
• In vivo skeletal localization properties of 99mTc complexes of large phosphonate ligands.

  1986cited by this paper
• Comparative evaluation of three diphosphonates: in vitro adsorption (C- 14 labeled) and in vivo osteogenic uptake (Tc-99m complexed).

  1980cited by this paper
• Uptake by bone of pyrophosphate, diphosphonates and their technetium derivatives.

  1978cited by this paper
• Bone scanning: radionuclidic reaction mechanisms.

  1976cited by this paper
• Comparison of 99mTc-labeled phosphate and phosphonate agents for skeletal imaging.

  1976cited by this paper
• The binding of pyrophosphate and two diphosphonates by hydroxyapatite crystals

  1973cited by this paper

• Comparative evaluation of 99mTc-MBIP-X/11[C] MBMP for visualization of 18 kDa translocator protein

  2019cites this paper
• Modified benzoxazolone (ABO‐AA) based single photon emission computed tomography (SPECT) probes for 18 kDa translocator protein

  2019cites this paper
• Synthesis and evaluation of a novel 99mTc nitrido radiopharmaceutical with alendronate dithiocarbamate as a potential bone‐imaging agent

  2018cites this paper
• Synthesis, Characterization, and Cytotoxic Activities of a Schiff Base Ligand and Its Binuclear Copper(II) and Manganese(III) Complexes

  2017cites this paper
• Future Perspectives of Bisphosphonates in Maxillofacial, Dental, and Medical Practice

  2015cites this paper
• Chemical design of (99m)Tc-labeled probes for targeting osteogenic bone region.

  2013cites this paper
• Synthesis, Biological Evaluation and Molecular Docking Studies of High‐Affinity Bone Targeting N,N'‐Bis (alendronate) Diethylenetriamene‐N,N'‐Triacetic Acid: A Bifunctional Bone Scintigraphy Agent

  2013cites this paper
• Synthesis and characterization of some new complexes of Cu(II), Ni(II) and V(IV) with Schiff base derived from indole-3-carboxaldehyde. Biological activity on prokaryotes and eukaryotes.

  2012cites this paper
• Preclinical evaluation of DO3P-AME-DO3P: a polyazamacrocyclic methylene phosphonate for diagnosis and therapy of skeletal metastases.

  2011cites this paper
• 99mTc(CO)3-labeled pamidronate and alendronate for bone imaging.

  2011cites this paper
• Pharmacoscintigraphy: a blazing trail for the evaluation of new drugs and delivery systems.

  2009cites this paper